<DOC>
	<DOCNO>NCT00630747</DOCNO>
	<brief_summary>Study TKT024EXT long-term , single-arm , open-label extension Study TKT024 , one year Phase 2/Phase 3 registration study . The primary objective extension study collect long-term safety clinical outcome data Mucopolysaccharidosis II ( MPS II ) , also know Hunter Syndrome , Phase 2/Phase 3 Study TKT024 . All patient enrol study receive weekly active treatment idursulfase , primary dose regimen investigate Study TKT024 . Hunter Syndrome X-linked recessive lysosomal storage disease cause deficiency iduronate-2-sulfatase , enzyme require catabolize glycosaminoglycans ( GAGS ) cell . As result , GAGs accumulate lysosome lead cellular engorgement , organomegaly , tissue destruction , organ system dysfunction . Hunter Syndrome rare disease estimate incidence 1 162,000 live birth .</brief_summary>
	<brief_title>Extension Study TKT024 Evaluating Long-Term Safety Clinical Outcomes MPS II Patients Receiving Idursulfase</brief_title>
	<detailed_description>Study TKT024EXT conduct 2 phase . The first phase ( `` Phase I '' ) 2 year ( 104 week ) duration consist weekly infusion IV idursulfase ( 0.5 mg/kg ) , collection patient ' safety clinical outcome . Week 105 define begin second phase study . The second phase ( `` Phase II '' ) consist weekly infusion IV idursulfase ( 0.5 mg/kg ) monitoring patient safety ( via collection adverse event , concomitant medication , vital sign ) . Study completion define time patient either transition commercially available idursulfase discontinue study . Idursulfase administer patient continuous IV infusion dose 0.5 mg protein per kg body weight ( 0.5 mg/kg ) . Final evaluation Study TKT024 , one-year predecessor Phase 2/Phase 3 registration study , serve baseline assessment TKT024EXT study . Forced vital capacity ( FVC ) 6-minute walk test ( 6MWT ) continue primary clinical outcome TKT024EXT study . Efficacy outcomes evaluate course 2 year determine 4-month interval first year ( ie , Weeks 18 , 36 , 53 ) 6-month interval second year ( ie , Weeks 79 105 ) . Safety outcomes assess throughout duration study . The safety clinical testing perform TKT024EXT study identical perform double-blind phase Study TKT024 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>Patient must complete doubleblind phase Study TKT024 , define complete Week 53 final evaluation . Patient , patient 's parent ( ) , legally authorize representative must voluntarily sign Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve informed consent form relevant aspect study explain discussed patient . Patient receive treatment investigational therapy iduronate2sulfatase Study TKT024 within past 60 day . Patient unable comply protocol ( e.g. , due medical condition cervical cord compression uncooperative attitude ) unlikely complete study , determine investigator . Patient experience adverse reaction study drug Study TKT024 , contraindicate treatment idursulfase . Patient known hypersensitivity component idursulfase .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hunter syndrome</keyword>
	<keyword>hunter syndrome</keyword>
	<keyword>hunter 's syndrome</keyword>
	<keyword>hunter disease</keyword>
	<keyword>hunter disease</keyword>
	<keyword>hunter 's disease</keyword>
	<keyword>MPS II</keyword>
	<keyword>MPSII</keyword>
	<keyword>MPS2</keyword>
	<keyword>MPS 2</keyword>
	<keyword>mucopolysaccharide</keyword>
	<keyword>lysosomal storage disease</keyword>
	<keyword>lysosomal storage disorder</keyword>
	<keyword>chronic ear infection</keyword>
	<keyword>enlarged adenoid</keyword>
	<keyword>mp symptom</keyword>
	<keyword>mp diagnosis</keyword>
	<keyword>mp ii therapy</keyword>
	<keyword>MPS II treatment</keyword>
	<keyword>ert treatment</keyword>
	<keyword>elaprase</keyword>
	<keyword>idursulfase</keyword>
	<keyword>iduronate sulfatase</keyword>
	<keyword>iduronate 2 sulfatase</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>hunter syndrome treatment</keyword>
	<keyword>hunter 's syndrome treatment</keyword>
	<keyword>hunter syndrome therapy</keyword>
	<keyword>hunter 's disease treatment</keyword>
	<keyword>mp society</keyword>
</DOC>